Indian firm’s mass spec division goes to AB Sciex, and Leica gets the microscopy and histopathology segment.

India-based Labindia Instruments is selling its mass spectrometry business to AB Sciex and its microscopy and histopathology business to Leica Microsystems. AB Sciex and Leica say that the transactions are a natural outcome of their respective supply arrangements with Labindia in India.

AB Sciex explains that its investment strategy in India is to combine its global resources, world-class scientific expertise, and product development leadership with well-established, local expertise, and on-site support to respond to the growing needs of India’s scientific community. The firm’s expansion of its commercial operations in India is expected to create new opportunities for partnerships and development.

Labindia has been supplying AB Sciex mass spectrometry instruments to the Indian market for the past 15 years. The transition of this business including customer relations, personnel, and application support facilities to AB Sciex is a direct result of the successful track record that it has had with Labindia.

“Expansion of AB Sciex’ commercial operations in India will strengthen our position and help us build on the success of Labindia’s mass spectrometry business as well as execute our growth strategy,” says Umesh Pawa, managing director, AB Sciex India. “By integrating Indian sales, service, and support functions into AB Sciex’ global resources and operational excellence, we will simplify the process for customers to do business with AB Sciex and drive the highest standard of support, further enhancing customer satisfaction levels.”

Leica Microsystems and Labindia, on the other hand, have worked together for more than 20 years. With its acquisition, Leica says that over 130 associates from Labindia have transferred over.

“Leica Microsystems’ expansion of its commercial operations in India creates extended opportunities for interaction, collaboration, and innovation to benefit all of our customers in the life sciences, industrial laboratories, and hospitals for both diagnostics and surgery,” explains Arnd Kaldowski, president of Leica Microsystems. “This acquisition will enable closer contact with our customers so that we can better support them in their day-to-day work.”

Previous articleGenzyme’s mAb for Multiple Sclerosis Succeeds in Second Phase III Trial
Next articleFirst Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results